Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Inoperable or Recurrent Breast Cancer
Interventions: DRUG: Eribulin Mesylate
Sponsor: Eisai Co., Ltd.